Filing Flows › Myriad Genetics (MYGN) › Q1 2026
Myriad Genetics (MYGN) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Myriad Genetics (MYGN) reported revenue of $200M for the first quarter 2026 (Q1 2026), +2% from a year earlier and -4% from the quarter before. Operating margin was -15.3%, net loss $34.1M (17.0% of revenue).
Myriad Genetics, Q1 2026: revenue $200M (+2% year over year), operating margin -15.3%, net loss $34.1M, operating cash flow −$15.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $200M | -4% | +2% |
| Operating profit | −$30.7M | — | — |
| Net earnings | −$34.1M | — | — |
| Operating cash flow | −$15.7M | -248% | — |
What changed
Revenue was $200.4M in Q1 2026, up 2% year over year and down 4% from the previous quarter. Cancer Care Continuum was the largest line at 60% of revenue. Mental Health added $7.3M year over year (up 24%), 162% of the total change. Prenatal Health declined 15%.
Gross margin was 68.7%, up 0.2 points from Q1 2025. Operating costs exceeded revenue by $30.7M, an operating margin of -15.3%. Operating expenses grew 3% against revenue growth of 2%. The quarter ended with a net loss of $34.1M, wider than the previous quarter's $7.9M loss.
Operating cash flow was −$15.7M. Non-cash charges added back $12.5M of depreciation and amortization and $6.5M of share-based compensation. Capital expenditures of $5.4M exceeded it, leaving free cash flow of −$21.1M.
Questions
What was Myriad Genetics' revenue in the first quarter 2026?
Myriad Genetics (MYGN) reported revenue of $200M for the first quarter 2026 (Q1 2026), +2% from a year earlier and -4% from the quarter before.
Was Myriad Genetics profitable in the first quarter 2026?
Operating loss was $30.7M (-15.3% of revenue) and net loss $34.1M.
Source: Myriad Genetics 10-Q on SEC EDGAR.